Answers are grounded in this paper and cite their sources.
Hepatocellular Carcinoma (HCC) with Portal Vein Tumor Thrombus (PVTT) is a highly advanced unresectable tumor with limited treatment options and a rather poor prognosis. Recently, atezolizumab plus bevacizumab was introduced as a new first-line combination therapy regimen for unresectable-HCC (u-HCC), but its use is restricted to patients with compensated liver function (ie, Child-Pugh [CP] class A liver function).
No takes yet. Share an insight, caveat, or question.
Toshihito Tanahashi (2023) studied this question.